- Design
- Descriptive analysis of claims data with database interaction screening
- Population
- Adolescents and adults with sickle cell disease and US commercial insurance; the 100 most prescribed drugs
- Primary outcome
- Proportion of commonly prescribed drugs with drug-drug interaction risk
- Effect
- 43 of 100 drugs; oxycodone prescribed to 40%, fentanyl to 18.5%
This analysis used a US commercial-insurance claims database (MarketScan) to identify the 100 most prescribed drugs for adolescents and adults with sickle cell disease. It then scored each for drug-drug interaction risk using a commercial interaction database.
Forty-three of the 100 drugs were associated with interaction risk. Inhibitors were more common than inducers, and CYP3A4 accounted for the largest share of interactions. Oxycodone (prescribed to 40%) and fentanyl (18.5%) are CYP3A4 substrates, and the authors flag the potentially serious consequences if a CYP3A4 inhibitor is added.
This is a prescribing-pattern and interaction-database study in insured US patients. It does not measure real adverse events, and the interaction ratings come from a database rather than from observed harms. The authors frame it as awareness for clinicians and a prompt for drug developers.
- Check for CYP3A4 inhibitors whenever a patient with sickle cell disease takes oxycodone or fentanyl.
- Include over-the-counter and herbal products in the medication review.
- Ask what changed before an unexpected opioid effect: a newly added inhibitor is a common cause.
- Record the full drug list at each admission for a vaso-occlusive crisis.
Why it matters
The drugs patients take most often are the ones most exposed to a single interaction pathway.
Don't overread it
The study counts database-listed interactions in insured US patients, not clinical events.
The statistics, in plain English
'Associated with interaction risk' means an interaction is listed in a database, not that harm was seen in these patients. Many listed interactions are minor or managed by dose adjustment.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free